Medical/Pharmaceuticals
Norgine welcomes TGA registration in Australia of IFINWIL® (eflornithine) for adults and children diagnosed with high-risk neuroblastoma (HRNB)[1]
* IFINWIL®: now TGA registered in Australia * Children diagnosed with neuroblastoma are on average just 2 years old2 * The average survival rate of children with HRNB is only 50%2 UXBRIDGE, England, April 17, 2025 /PRNewswire/ -- Norgine is pleased to announce that the Australian Therapeutic...
2025-04-17 08:01
2403
Norgine strengthens rare disease portfolio with acquisition of Theravia
Acquisition of Theravia from Mérieux Equity Partners represents meaningful step forward in Norgine's strategy for sustainable growth, adding a complementary portfolio of rare disease medicines Transaction further establishes Norgine's position as a partner of choice for commercialising rare and ...
2025-04-17 08:01
2473
Saudi Arabia and France Strengthen Health Cooperation Through Strategic Agreements in Biotech and Digital Health
PARIS, April 17, 2025 /PRNewswire/ -- On the second day of an official visit to France, His Excellency Fahad Abdulrahman AlJalajel, Minister of Health of the Kingdom of Saudi Arabia, held bilateral meetings with senior French officials including Minister for Labour, Health, Solidarity and Familie...
2025-04-17 06:21
3550
Terumo Blood and Cell Technologies Names Patrick Daly as Chief Business Officer
Daly, a 30-year veteran of the healthcare industry, is the latest leadership
addition to help Terumo BCT unite business areas and fuel enterprise growth
LAKEWOOD, Colo., April 16, 2025 /PRNewswire/ -- Terumo Blood and Cell
Technologies
2025-04-17 03:00
2892
Terumo Health Outcomes Now Offers FDA-Cleared Medis QFR® 3.0 Software for Coronary Physiology Assessment in the US
– Innovative AI software supports hospital adoption of advanced tools to improve cath lab workflow and patient comfort – SOMERSET, N.J., April 16, 2025 /PRNewswire/ -- Terumo Health Outcomes (THO), a division of Terumo Interventional Systems (TIS), today announced that Medis QFR 3.0, an FDA-cle...
2025-04-17 01:10
3217
Henlius 2025 Global R&D Day: Harnessing the Power of Innovation to Propel Global Strategy to New Heights
SHANGHAI, April 16, 2025 /PRNewswire/ -- Henlius (2696.HK) held its 2025 Global R&D Day under the theme of "Collaborate to Create". Senior executives from Henlius gathered with leading experts, scholars, and heads of innovation from across the industry to engage in in-depth discussions on the lat...
2025-04-16 23:30
3431
Putting Patients First, Co-Creating a Bright Future for Human Health: Henlius Releases 2024 ESG Report
SHANGHAI, April 16, 2025 /PRNewswire/ -- On April 15, 2025, Henlius (2696.HK) released the "2024 Environmental, Social, and Governance (ESG) Report" (hereinafter referred to as the "ESG Report" or "Report"). This marks the sixth consecutive year that the company has submitted an ESG-related repor...
2025-04-16 23:22
2974
Transforming Lives with TAVI: A Milestone in Aortic Stenosis Treatment
MANILA, Philippines, April 16, 2025 /PRNewswire/ -- The Philippine Heart Center has reached a significant milestone by successfully performing six Transcatheter Aortic Valve Implantation (TAVI) procedures in a single day. This groundbreaking technique offers a minimally invasive alternative to op...
2025-04-16 20:32
2780
Global Health Innovators recognised with Abu Dhabi Global Health Week Innovation Awards for transformative impact
* Winners of the ADGHW Innovation Awards 2025 addressed prenatal gene editing, robotic organ transplantation, precision drug delivery, and novel pain treatments * Recipients include the Children's Hospital of Philadelphia, University of Pennsylvania, King Faisal Specialist Hospital & Research...
2025-04-16 20:15
2750
Global Health Innovators recognised with Abu Dhabi Global Health Week Innovation Awards for transformative impact
* Winners of the ADGHW Innovation Awards 2025 addressed prenatal gene editing, robotic organ transplantation, precision drug delivery, and novel pain treatments * Recipients include the Children's Hospital of Philadelphia, University of Pennsylvania, King Faisal Specialist Hospital & Research...
2025-04-16 19:36
13349
Fullerton Health Indonesia Launches First Executive Health Screening Centre Offering Exclusive, Private and Customised Screening in Jakarta
JAKARTA, Indonesia, April 16, 2025 /PRNewswire/ -- Fullerton Health Indonesia today officially launched its first Executive Health Screening Centre (EHS) in Jakarta, the fifth such centre in the Fullerton Health Group's executive health screening portfolio acrossAsia. The 700-square metre centre o...
2025-04-16 14:00
3174
The Lancet Child & Adolescent Health Publishes Phase III Trial and 24-Month Follow-Up Results of Ziresovir for RSV in Infants Under 6 Months
SHANGHAI, April 16, 2025 /PRNewswire/ -- The Lancet Child & Adolescent Health, a leading international journal in pediatric and adolescent medicine, has published the Phase III clinical trial results ofziresovir, a novel RSV-targeted antiviral drug developed by Shanghai Ark Biopharmaceutical Ltd....
2025-04-16 09:00
3626
IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate
MELBOURNE, Australia and INDIANAPOLIS, April 16, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces preliminary results from the Phase 2 IPAX-Linz study of TLX101 (131 I-iodofalan[1]) in recurrent high-grade glioma (brain cancer), substan...
2025-04-16 06:45
2614
XellSmart's Allogeneic iPSC-derived Cell Therapies for Parkinson's Disease and ALS Officially Approved by the U.S. FDA for Phase I Clinical Trials
SUZHOU, China, April 15, 2025 /PRNewswire/ -- In January 2025 (U.S. time), the U.S. Food and Drug Administration (FDA) officially approved the Investigational New Drug (IND) application submitted by XellSmart Biopharmaceutical (Suzhou) Co., Ltd. for its universal allogeneic off-the-shelf iPS-deri...
2025-04-15 21:10
2960
SECuRE trial update: First patient treated in the Phase II Cohort Expansion
HIGHLIGHTS * The first of the planned 24 participants in the Cohort Expansion Phase (Phase II) of the SECuRE trial has been treated with their first dose of 8 GBq of67Cu-SAR-bisPSMA.This follows the recent recommendation by the Safety Review Committee (SRC) after the successful completion of t...
2025-04-15 21:02
2781
Pilatus Biosciences to Present Research on PLT012 at AACR 2025
Novel Immunometabolism Approach Targets Immune-Cold Solid Tumors DOVER, Del. and EPALINGES, Switzerland, April 15, 2025 /PRNewswire/ -- Pilatus Biosciences, pioneering biologics targeting metabolic checkpoints, will present new research on its lead candidate, PLT012, at the American Association ...
2025-04-15 20:35
2044
Vantage Foundation Visits SOS Children's Villages Portugal: Addressing Neglect and Breaking the Cycle
LISBON, Portugal, April 15, 2025 /PRNewswire/ -- Neglect is one of the most pervasive yet overlooked threats to a child's well-being. Unlike abandonment, neglect often goes unnoticed—leaving children trapped in cycles of chronic emotional harm, broken trust, and long-term developmental struggles....
2025-04-15 17:05
3734
Open nominations for the BIAL Award in Biomedicine 2025 with an increased amount to €350,000
Created to distinguish the most remarkable scientific discoveries in the biomedical field, this international award has been granted a growing reputation as a prelude to the Nobel Prize since it has distinguished in a former edition two authors subsequently honoured with the Nobel Prize in Medic...
2025-04-15 15:00
2692
Rege Nephro Acquires Tamibarotene-Related Assets from Syros Pharmaceuticals for U.S. Clinical Trials
KYOTO, Japan, April 15, 2025 /PRNewswire/ -- Rege Nephro Co., Ltd. (Headquarter: Kyoto, Japan; Chief Executive Officer: Akifumi Morinaka) has announced that it has successfully acquired Tamibarotene-related clinical and non-clinical assets from Syros Pharmaceuticals, Inc. (Headquarters:Boston, MA;...
2025-04-15 13:20
2331
Wang Qunbin: Leveraging Innovation and Global Operational Strengths to Contribute "Fosun Power" to the Development of Hainan Free Trade Port
HONG KONG and SHANGHAI, April 15, 2025 /PRNewswire/ -- On April 14, the 2025 Hainan Free Trade Port Global Investment Promotion Conference was held inHaikou . Jointly hosted by the People's Government ofHainan Province and the Ministry of Commerce, the conference is one of the key events in the 20...
2025-04-15 12:05
3604
Week's Top Stories
Most Reposted
UFO SIM Launches in Australia, The Ultimate Travel eSIM Starting at Just AU$2/GB
[Picked up by 310 media titles]
2026-04-01 11:03
Sustainable Tourism Impact Fund Expands Investments Across Southeast Asia
[Picked up by 309 media titles]
2026-04-03 11:30
Surfin Meta Digital Technology signs MOU with the Philippine Social Security System to explore digital financial service enhancements
[Picked up by 307 media titles]
2026-04-01 09:00
Visa cements global K-pop connection as Worldwide Tour Sponsor for "BTS WORLD TOUR 'ARIRANG'"
[Picked up by 305 media titles]
2026-04-06 10:00
UTP Advances Across Key Disciplines in QS World University Rankings By Subject 2026 - Petroleum Engineering Among World's Top 10
[Picked up by 297 media titles]
2026-04-06 16:46
Most Read
NYSE Content Update: Versigent To Ring Opening Bell As its Shares Debut for Trade
2026-04-01 22:44
5948
LightInTheBox Files 2025 Annual Report on Form 20-F
2026-04-02 20:00
5546
